Etiology
May involve the arrest of maturation of the osteoblasts caused by USP6 overexpression and dysregulation of autocrine BMP (bone morphology protein) signaling (Lau et al., 2010) .
Epidemiology
Usually seen in patients aged 10-20 years; represents about 5% of primary bone tumours; slightly more frequent in female patients.
Clinics
Forms a spongy hemorrhagic mass; symptoms are pain, swelling, pathological fractures. Two cases to date was found with a t(17;17)(p13;q21), a 8-year-old boy with a tumor of the soft tissues, and a 13-year-old boy with a tumor located in the tibia (Oliveira et al., 2005; Panagopoulos et al., 2008) .
Treatment
Surgical curetage.
Prognosis
Recurrence occurs in one fourth of cases.
Cytogenetics

Cytogenetics Morphological
The t(17;17)(p13;q21) was the sole anomaly.
Genes involved and proteins
COL1A1
Location 17q21 Protein Two pro a1(I) chain associate in trimers with one pro a2(I) chain to form the type I collagen fibrils after proteolysis. Constituent of the extra cellular matrix in connective tissue of bone, skin, tendon, ligament, teeth. Germinal mutations COL1A1 has been found mutated in osteoporosis, osteogenesis imperfecta types I-IV, Ehlers-Danlos types I and VIIA, and Caffey disease (Stover and Verrelli, 2011) .
USP6
Location 17p13 Protein USP6, also called TRE17/ubiquitin-specific protease 6 (USP6), is a deubiquitinase. It is the first deubiquitinating enzyme to activate NF-KB, and requires both catalytic subunits of IKK (IKKalpha and IKKbeta) (Pringle et al., 2011) .
Result of the chromosomal anomaly
Hybrid Gene
Description 5' COL1A1 -3' USP6
Fusion Protein
Description Fusion of the exon 1 of COL1A1 to a splicing variant of USP exon 1 in the case reported in Oliveira et al., 2005. 
